Introduction Objective cutaneous metastasis from carcinoma of the uterine cervix is an uncommon occurrence. The outcome of patients with skin metastasis is usually poor as they are often associated with locoregional recurrence. This metastasis impairs the quality of life and shortens survival. Consequently, physicians should be aware of the possible existence of skin metastasis in cervical cancer. Clinical suspicion should lead to a careful additional evaluation whenever a cutaneous nodule presents in the course of the disease. Case report We report a rare case of metastasis from squamous cell carcinoma of cervix to the umbilicus. The patient was diagnosed with stage IIB FIGO. Four months after chemoradiation patient presented with a nodule in the umbilical region. Biopsy performed and metastatic squamous cell carcinoma was diagnosed. Patient underwent salvage therapy with paclitaxel and carboplatin. Conclusion To the best of our knowledge, this is a rare reported occurrence of umbilical metastasis in cervical cancer without prior laparotomy or laparoscopy. This metastatic lesion has a grave prognosis and the mean survival is about 3 months like our case.

No abstract

Ovarian carcinoma is the second most common gynecologic cancer and the leading cause of death from gynecologic malignancy. The management of recurrent ovarian cancer has been individualized. Reports of recurrence in supradiaphragmatic lymph nodes are rare. We describe the finding of metastatic tumor involving cervical, submandibular and suboccipital lymph nodes in a 77-year-old patient with ovarian carcinoma. Keywords: scalene lymph node, ovarian cancer, lymphadenopathy, recurrence   doi: 10.3329/jom.v10i2.2830   J MEDICINE 2009; 10 : 128-131

Sexual dysfunction (SDF) is a common sequel to cancer treatment which affects the quality of life in women treated with pelvic radiotherapy. The aim of this study was to evaluate the safety, symptom resolution and objective improvement the injection of autologous platelet released growth factor (APRGF) for treatment of SDF in cited patients. This prospective pilot study enrolled 10 cancer-free patients with SDF who underwent pelvic radiotherapy at least 5 years ago, randomly. Each patient was received 1-2 cc APRGF within four weeks and all patients were re-evaluated at eight weeks and six months. CD34 immuno histochemistry and Masson’s trichrome staining were performed on vaginal biopsy section for angiogenesis and fibrosis assay respectively. Sexual satisfaction after the injection of APRFG was clinically difference and the entire patient had sexual satisfaction. In the patient’s follow-up, none of them needs to repeat the treatment. Our results declared that APRGF injection was effective and symptoms were disappeared in the entire patients. Significant objective improvements in vaginal diameter (mean before injection, 6.5 cm vs 7.1 cm after injection) (p-value = 0.001) and vaginal flexibility (mean before treatment, 0.72 cm vs 1.85 cm after injection) (P-value = 0.026) were observed. Characteristics of discharge before the injection in 60% of patients were included dry vagina and 40% had mild discharge but after injection 40% of patients had moderate and also 60% had mild and sufficient discharge (P-value= 0.190). Overally, our patients reported better sexual function and showed better vaginal function indexes, after APRFG injection.